Dana-Farber’s Belfer Institute for Applied Cancer Science, Evotec sign oncology research deal

The collaboration will focus on validating epigenetic targets for cancer indications and establishing the drugability of the selected target families.

Evotec CEO Dr Werner Lanthaler said, "We are very proud to have entered into this collaboration with Dana-Farber and the Belfer Institute for Applied Cancer Science, which perfectly matches our innovation strategy as described in Evotec’s Action Plan 2016."

Under the deal, Evotec, Dana-Farber and Dana-Farber’s Belfer Institute for Applied Cancer Science will leverage existing expertise and platforms to invest in enabling technologies, experimental target validation and the generation of chemical matter.

The Belfer Institute for Applied Cancer Science research head Dr Jessie English said, "This pioneering partnership provides a unique opportunity to combine Evotec’s drug discovery capabilities with Belfer Institute for Applied Cancer Science and Dana-Farber Cancer Institute’s expertise in oncology disease biology to accelerate the development of new medicines for patients."

Additional details of the deal were not revealed.